Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In multivariate analysis, Aspergillus spp. co-infection was the single independent factor associated with anti-NTM treatment (OR, 5.3 [95% CI 1.1 to 25.4]; p = 0.036) (Table 3).Bivariate analysis of the factors associated with treatment initiation in adult patients with nontuberculous mycobacterial lung disease without systemic immunodeficiencyTested variablesTreated patients (n=25)Untreated patients (n=26) P-value OR [95% CI] Clinical criteria BMI < 18 (kg/m2)13/24 (54.2)5/23 (21.7) 0.026 4.25 [1.18-15.2] Weight loss > 5%17 (68)10 (38.5) 0.05 3.4 [1.07-10.77] fatigue13 (52)7 (27)0.0712.94 [0.9-9.46] chronic cough16 (64)14 (54)0.5721.52 [0.49-4.69] night sweats5 (20)3 (11.5)0.4651.92 [0.41-9.05] hemoptysis8 (32)1 (3.8) 0.026 11.8 [1.3-102.8] Microbiological criteria AFB-positive sputum sample on direct examination13 (52)8 (30.8)0.1602.44 [0.77-7.65] NTM-positive culture NTM on lower respiratory tract sample2 (1-2.3)1 (1-1.8) 0.044 1.79 [1-3.2] Functional criteria FEV1 (L)1.6 (1.2-2.2)1.9 (1.2-2.5)0.5540.72 [0.34-1.51] Immunological and nutritional status total lymphocyte count (G/L)1.3 (1.2-1.7)1.4 (1.1-2.1)0.3880.95 [0.86-1.04] CD4+ lymphocyte count (%)54 (4.5-61.5)40 (37.8-44.3) 0.031 1.07 [0.95-1.21] serum albumin (mg/L)39.5 (36-43)39 (33-42.5)0.4811.05 [0.97-1.14] serum pre-albumin (mg/L)0.21 (0.15-0.24)0.22 (0.15-0.25)0.9741.25 [0-1.48] vitamin D deficiency6/10 (60)6/7 (86)0.3380.25 [0.02-2.95] Co-infection(s) Mycobacterium tuberculosis1 (4)1 (4)0.351.04 [0.06-17.6] Pseudomonas spp.2 (8)3 (11.5)10.68 [0.1-4.4] Aspergillus spp.15 (60)5 (19.2) 0.004 6.3 [1.8-22.2] Radiologic features at diagnosis nodule(s) (≥ 10mm)12 (48)7/23 (30)0.252.11 [0.65-6.9] cluster(s) of micronodules (< 5mm)16 (64)10/23 (44)0.2462.31 [0.72-7.4] cavitation(s)18 (72)8/23 (35) 0.019 4.82 [1.42-16.4] bronchiectasis14 (56)11/23 (48)0.7731.39 [0.45-4.3] emphysema9 (36)11/23 (48)0.5590.61 [0.19-1.95] Radiologic review regression8/23 (35)4/13 (31)11.2 [0.28-5.15] stabilization9/23 (39)6/13 (46)0.7360.75 [0.19-2.97] worsening6/23 (26)3/13 (23)11.18 [0.24-5.8]NOTE Data are No. (%) of patients, unless otherwise indicated.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity

Study design awaiting verification · BMC Infectious Diseases · 2018

Original publication title

A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity

Judith Provoost; Florent Valour; Delphine Gamondes; Sandrine Roux; Nathalie Freymond; Emilie Perrot; Pierre-Jean Souquet; Lize Kiakouama-Maleka; Christian Chidiac; Gérard Lina; Oana Dumitrescu; Agathe Sénéchal; Florence Ader

© The Author(s). 2018

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The most relevant variable associated with anti-NTM treatment initiation was Aspergillus spp. co-infection. Radiological regression or stabilization of pulmonary lesions was not different between the treated and untreated patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Nontuberculous mycobacteria (NTM) lung diseases are increasingly recognized as chronic opportunistic infections, occurring in individuals with a wide variety of underlying conditions. In the absence of systemic immunodeficiency, decision of NTM lung disease treatment must relies on a careful risk/benefit assessment, given the requirement of long-term administration of multidrug therapies supported by limited evidence. The primary objective was to identify the factors associated with anti-NTM treatment initiation. Clinical and radiological outcome upon treatment were studied.

Source: Background

Abstract: What methods does the paper describe?

This retrospective, single center study (2013 to 2016, 45 months) addressed the criteria supporting treatment decision among adults with NTM lung disease without systemic immunodeficiency at our institution, with the assigned goal to harmonize the practice. All patients matched the current international definitions of NTM lung disease according to the American Thoracic Society criteria. Factors associated with anti-NTM treatment were investigated by conditional logistic regression. Clinical and radiological outcomes of treated and untreated NTM-disease cases were examined. Mortality rate was assessed. An expert radiologist conducted a blinded computed tomography (CT)-scan review of the treated and untreated patients.

Source: Methods

Abstract: Results

Among 51 cases of NTM lung diseases, 25 (49%) received anti-NTM treatment. In univariate analysis, a body mass index (BMI) < 18 kg/m2 (odds ratio (OR), 4.2 [95% confidence interval (CI) 1.2 to 15.2]; p = 0.042), hemoptysis (OR, 11.8 [95% CI 1.35 to 12.9]; p = 0.026), excavation(s) (OR, 4.8 [95% CI 1.4 to 16.4], p = 0.012), prior anti-NTM treatment (OR, 5.65 [95% CI 1.06 to 29.9]; p = 0.042), Aspergillus spp. co-infection (OR, 6.3 [95% CI 1.8 to 22.2]; p = 0.004) were associated with treatment initiation.

In multivariate analysis, Aspergillus spp. co-infection was the only independent determinant of treatment initiation (OR, 5.3 [95% CI 1.1 to 25.4]; p = 0.036). Twenty-one (81%) patients received ≥3 anti-NTM drugs. Median treatment duration and follow-up were 36.3 (interquartile range [IQR], 13.1 to 64.4) weeks and 17.1 (IQR, 8.7 to 27.1) months, respectively. Regarding radiological outcome, 85 CT-scans were reviewed, showing similar rates of regression or stabilization in treated and untreated patients. Overall mortality rate was not different in treated and untreated patients.

Source: Results

Abstract: Conclusion

The most relevant variable associated with anti-NTM treatment initiation was Aspergillus spp. co-infection. Radiological regression or stabilization of pulmonary lesions was not different between the treated and untreated patients.

Source: Conclusion
Authors’ abstract

Background

Nontuberculous mycobacteria (NTM) lung diseases are increasingly recognized as chronic opportunistic infections, occurring in individuals with a wide variety of underlying conditions. In the absence of systemic immunodeficiency, decision of NTM lung disease treatment must relies on a careful risk/benefit assessment, given the requirement of long-term administration of multidrug therapies supported by limited evidence. The primary objective was to identify the factors associated with anti-NTM treatment initiation. Clinical and radiological outcome upon treatment were studied.

Methods

This retrospective, single center study (2013 to 2016, 45 months) addressed the criteria supporting treatment decision among adults with NTM lung disease without systemic immunodeficiency at our institution, with the assigned goal to harmonize the practice. All patients matched the current international definitions of NTM lung disease according to the American Thoracic Society criteria. Factors associated with anti-NTM treatment were investigated by conditional logistic regression. Clinical and radiological outcomes of treated and untreated NTM-disease cases were examined. Mortality rate was assessed. An expert radiologist conducted a blinded computed tomography (CT)-scan review of the treated and untreated patients.

Results

Among 51 cases of NTM lung diseases, 25 (49%) received anti-NTM treatment. In univariate analysis, a body mass index (BMI) < 18 kg/m2 (odds ratio (OR), 4.2 [95% confidence interval (CI) 1.2 to 15.2]; p = 0.042), hemoptysis (OR, 11.8 [95% CI 1.35 to 12.9]; p = 0.026), excavation(s) (OR, 4.8 [95% CI 1.4 to 16.4], p = 0.012), prior anti-NTM treatment (OR, 5.65 [95% CI 1.06 to 29.9]; p = 0.042), Aspergillus spp. co-infection (OR, 6.3 [95% CI 1.8 to 22.2]; p = 0.004) were associated with treatment initiation.

In multivariate analysis, Aspergillus spp. co-infection was the only independent determinant of treatment initiation (OR, 5.3 [95% CI 1.1 to 25.4]; p = 0.036). Twenty-one (81%) patients received ≥3 anti-NTM drugs. Median treatment duration and follow-up were 36.3 (interquartile range [IQR], 13.1 to 64.4) weeks and 17.1 (IQR, 8.7 to 27.1) months, respectively. Regarding radiological outcome, 85 CT-scans were reviewed, showing similar rates of regression or stabilization in treated and untreated patients. Overall mortality rate was not different in treated and untreated patients.

Conclusion

The most relevant variable associated with anti-NTM treatment initiation was Aspergillus spp. co-infection. Radiological regression or stabilization of pulmonary lesions was not different between the treated and untreated patients.

Publication and source details

Original title: A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity

Judith Provoost; Florent Valour; Delphine Gamondes; Sandrine Roux; Nathalie Freymond; Emilie Perrot; Pierre-Jean Souquet; Lize Kiakouama-Maleka; Christian Chidiac; Gérard Lina; Oana Dumitrescu; Agathe Sénéchal; Florence Ader

BMC Infectious Diseases · 2018

© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:50:25.574235+00:00

DOI: 10.1186/s12879-018-3559-x · PMC6295085